Ranaz reports strong sales growth in the second quarter of 2008



    
    - Increase of approximately 93% to $6.7 million compared to the second
      quarter of 2007
    - Growth across the board for all markets and all products
    

    MONTREAL, Aug. 5 /CNW Telbec/ - Ranaz Corporation ("Ranaz") (TSX-V: RNZ),
a company specialized in the manufacturing and marketing of protein and
dietary supplements, today reports its sales figures for the second quarter
and six-month period ended June 30, 2008. Ranaz will release its full
financial results for the period on August 29, 2008.
    Ranaz expects its second quarter sales to increase by about 93% to
approximately $6,700,000 from $3,471,695 for the same period in 2007. Ranaz
expects its sales for the first six months of the year to total approximately
$10,890,000, up about 70% from $6,384,587 in 2007.
    "Sales of ProtiLife, Protidiet and BarTech were higher in all our
markets, and demand for our products continues to grow despite ongoing
economic uncertainty," said Jean Bourassa-Marineau, President and founder of
Ranaz. "As we said last quarter, our priority is to achieve operating
profitability as soon as possible while continuing to expand."
    Ranaz is currently preparing its second quarter results. The above
forecasts are based on current estimates and subject to change.

    About Ranaz Corporation

    Ranaz is a corporation specializing in the manufacture and marketing of
protein and dietary supplements. Its mission is to design, develop and market
nutritional, protein and dietary supplements under its own corporate brands
and concepts, such as Protidiet and ProtiLife, as well as under private
labels.

    Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, constitute
forward-looking statements. This release also includes financial information
of which, as of the date of this news release, Ranaz's independent auditors
have not reviewed. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Ranaz's control.
Such risks include but are not limited to: the impact of general economic
conditions, changes in the regulatory environment in the jurisdictions in
which Ranaz does business, stock markets volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation, as well as
other risks disclosed in public filings of Ranaz. Consequently, while Ranaz
believes that the assumptions upon which the forward-looking statements
(particularly financial) are based are reasonable, actual future results may
differ materially from the anticipated results expressed in the
forward-looking statements, and can give no assurance that these assumptions
will prove to be correct. The reader should not place undue reliance, if any,
on the forward-looking statements included in this news release. These
statements speak only as of the date made and Ranaz is under no obligation and
disavows any intention to update or revise such statements as a result of any
event, circumstances or otherwise.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.
    %SEDAR: 00024418EF




For further information:

For further information: Ranaz Corporation: Martin Vidal, Executive Vice
President and Chief Financial Officer, (450) 491-7106, Ext. 213,
martinv@ranazcorporation.com; SOLAK Communications: François Kalos, President,
(450) 993-0828, kalos@solak.ca; Media: Impact Communication: Carlo
Tarini,President, (514) 916-2436, tarini@impact-com.ca

Organization Profile

Ranaz Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890